RIGEL PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.9822 USD | -0.22% |
|
-19.49% | -32.26% |
| May. 07 | Transcript : Rigel Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024 | |
| May. 07 | Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Posts Q1 Revenue $29.5M, vs. Street Est of $31.5M | MT |
Presenter SpeechKalpit Patel (Analysts)All right. Good afternoon, everyone. I'm Kalpit Patel, ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.
Calendar
2024-05-22
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
0.9822
USD
Average target price
4.533
USD
Spread / Average Target
+361.55%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -32.26% | 172M | |
| +5.66% | 111B | |
| +11.23% | 105B | |
| -2.79% | 21.93B | |
| -12.15% | 22.34B | |
| -5.48% | 18.59B | |
| -36.52% | 18.12B | |
| -10.09% | 16.96B | |
| +3.33% | 13.7B | |
| +36.58% | 12.45B |
- Stock Market
- Equities
- RIGL Stock
- News Rigel Pharmaceuticals, Inc.
- Transcript : Rigel Pharmaceuticals, Inc. Presents at B. Riley Securities' 3rd Annual Oncology Conference, Jan-18-2023 03
